Clinical and histopathological findings of patients with orbital granulomatosis with polyangiitis cases refractory to rituximab.
Rituximab, a monoclonal antibody that targets CD20 receptors on mature B lymphocytes, is used in various diseases, including granulomatosis with polyangiitis (GPA) and difficult-to-treat orbital inflammatory diseases. We aimed to describe clinical and histopathologic findings in patients treated with rituximab refractory GPA who had post-rituximab orbital biopsies. Retrospective review. Patients with orbital GPA refractory to rituximab. We examined the clinical outcomes, imaging results, and histopathological findings of all patients from September 1, 1994, through July 1, 2017, with a diagnosis of orbital GPA who, after treatment with rituximab, required an orbital excisional biopsy for refractory orbital disease. Among the 7 patients included the clinical indication for biopsy was pain (n = 3), new mass lesion despite treatment (n = 2), and persistent lesion despite treatment (n = 2). Post-rituximab biopsies showed marked collagenized fibrous tissue, with areas of concentric fibrosis resembling the framework of pre-existing lymphoid follicles, and minimal residual lymphocytic infiltrates (n = 7). Three patients had entrapped nerves. Four biopsies showed active inflammation; clinically, all patients were not responding to treatment. This study highlights the clinical and histopathological changes seen in patients with orbital GPA refractory to rituximab therapy. The post-rituximab biopsies show marked fibrosis in all patients. Four patients had active inflammation without evidence of entrapped nerves, whereas 3 patients had entrapped nerves and no active inflammation on their biopsies. Knowledge of the histopathology may guide future management decisions in patients with orbital GPA refractory to rituximab treatment.